Valneva SE: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:Valneva SE}} | ||
}} | |||
'''Valneva SE''' is a | [[File:Valneva logo.svg|thumb|right|Valneva SE logo]] | ||
'''Valneva SE''' is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is headquartered in [[Saint-Herblain]], [[France]], and operates globally. | |||
==History== | ==History== | ||
Valneva was | Valneva SE was formed in 2013 through the merger of [[Vivalis SA]] and [[Intercell AG]]. The merger combined Vivalis's expertise in vaccine development and Intercell's innovative vaccine technologies. Since its inception, Valneva has focused on developing vaccines for infectious diseases, leveraging its proprietary technology platforms. | ||
==Technology Platforms== | |||
Valneva utilizes several proprietary technology platforms in its vaccine development efforts: | |||
* '''Vero-cell platform''': This platform is used for the production of inactivated whole virus vaccines. It is a well-established technology that Valneva employs for its [[Japanese encephalitis]] and [[COVID-19]] vaccine candidates. | |||
* '''EB66® cell line''': Originally developed by Vivalis, this cell line is used for the production of vaccines and therapeutic proteins. It is derived from duck embryonic stem cells and is known for its high yield and scalability. | |||
* '''IC31® adjuvant''': This adjuvant technology enhances the immune response to vaccines. It is used in several of Valneva's vaccine candidates to improve their efficacy. | |||
* ''' | ==Vaccine Portfolio== | ||
* ''' | Valneva's vaccine portfolio includes both marketed products and candidates in various stages of development: | ||
* ''' | |||
* '''IXIARO®''': A vaccine for the prevention of Japanese encephalitis, a mosquito-borne viral infection. It is approved in several countries and is primarily used by travelers and military personnel. | |||
* '''VLA2001''': A COVID-19 vaccine candidate based on the inactivated whole virus approach. It is designed to provide broad protection against the SARS-CoV-2 virus. | |||
* '''VLA1553''': A single-shot vaccine candidate for [[Chikungunya]], a mosquito-borne viral disease. It is currently in clinical trials. | |||
==Research and Development== | ==Research and Development== | ||
Valneva invests | Valneva invests significantly in research and development to expand its vaccine portfolio. The company collaborates with various organizations, including government agencies and pharmaceutical companies, to advance its vaccine candidates. | ||
== | ==Global Operations== | ||
Valneva has | Valneva operates manufacturing sites in [[Scotland]] and [[Sweden]], and has offices in several countries, including the [[United States]], [[Austria]], and [[United Kingdom]]. The company markets its products globally and continues to expand its international presence. | ||
==Related pages== | ==Related pages== | ||
* [[Vaccine]] | |||
* [[Infectious disease]] | |||
* [[Biotechnology]] | * [[Biotechnology]] | ||
[[Category: | [[Category:Pharmaceutical companies of France]] | ||
[[Category:Vaccine producers]] | [[Category:Vaccine producers]] | ||
[[Category:Companies established in 2013]] | [[Category:Companies established in 2013]] | ||
Latest revision as of 03:46, 13 February 2025
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is headquartered in Saint-Herblain, France, and operates globally.
History[edit]
Valneva SE was formed in 2013 through the merger of Vivalis SA and Intercell AG. The merger combined Vivalis's expertise in vaccine development and Intercell's innovative vaccine technologies. Since its inception, Valneva has focused on developing vaccines for infectious diseases, leveraging its proprietary technology platforms.
Technology Platforms[edit]
Valneva utilizes several proprietary technology platforms in its vaccine development efforts:
- Vero-cell platform: This platform is used for the production of inactivated whole virus vaccines. It is a well-established technology that Valneva employs for its Japanese encephalitis and COVID-19 vaccine candidates.
- EB66® cell line: Originally developed by Vivalis, this cell line is used for the production of vaccines and therapeutic proteins. It is derived from duck embryonic stem cells and is known for its high yield and scalability.
- IC31® adjuvant: This adjuvant technology enhances the immune response to vaccines. It is used in several of Valneva's vaccine candidates to improve their efficacy.
Vaccine Portfolio[edit]
Valneva's vaccine portfolio includes both marketed products and candidates in various stages of development:
- IXIARO®: A vaccine for the prevention of Japanese encephalitis, a mosquito-borne viral infection. It is approved in several countries and is primarily used by travelers and military personnel.
- VLA2001: A COVID-19 vaccine candidate based on the inactivated whole virus approach. It is designed to provide broad protection against the SARS-CoV-2 virus.
- VLA1553: A single-shot vaccine candidate for Chikungunya, a mosquito-borne viral disease. It is currently in clinical trials.
Research and Development[edit]
Valneva invests significantly in research and development to expand its vaccine portfolio. The company collaborates with various organizations, including government agencies and pharmaceutical companies, to advance its vaccine candidates.
Global Operations[edit]
Valneva operates manufacturing sites in Scotland and Sweden, and has offices in several countries, including the United States, Austria, and United Kingdom. The company markets its products globally and continues to expand its international presence.
